The Enoo Protocol


Environmental aging over time may play substantial role in oocyte aging. Nevertheless, increasingly poor oocyte quality in Premature Ovarian Failure (POF) or with advancing female age may actually be due to aging of the ovarian micro-environment, in which follicles and eggs mature after recruitment. Primordial follicles are immature and minuscule in size, which means they have almost no metabolic needs and well protected from environmental influences. However, during recruitment and maturation, follicles become extremely dependent on ovarian stromal micro-environment in which they mature. Stromal environment, as any other tissue is regulated by growth factors (GF). Successful delivery of stem cells through ovarian artery by IVI group in Spain and assessment of Dr Tilley’s research based on restoration of fertility following bone marrow transplantation , indicates that growth factors play key role in regulation of ovarian stromal tissue.

Different approaches have been reported as possibly effective for reversing premature ovarian failure, diminished ovarian reserve in peri-menopausal subjects. A team of researchers at Harvard University injected murine ovaries with growth factors, and mature eggs appeared to develop from ovarian stem cells. They stated that the introduction of isolated platelets directly into the ovaries might trigger a resurgence in oocyte production . Centers in Europe and the Middle East have reported success in Premature Ovarian Failure (POF), Diminished Ovarian Reserve (DOR), perimenopause, embryo implantation issues through injection of the subject’s’ own PRP into ovaries or Uterine Cavity and resulted in multiple pregnancies for subjects that previously had no hope. First report on successful application of PRP for IVF subjects was recently published in US. Ovarian rejuvenation, regardless of the influence of gonadotropins, is being reported through two other techniques: ovarian fragmentation and the infusion of stem cells into the ovarian artery. These techniques allowed for a partial reversal of the aging process of the ovary and they activated the dormant follicles, which would otherwise stay in the ovary. However, these techniques are quite invasive and not approved in US.

The Enoo Protocol

Our History

6 years ago, Neokine Laboratories made a discovery of their own. We developed a method that allows to harness platelets growth factors in more physiological and extremely effective and standardized manner. That in turn allows for elimination of variability in PRP preparations and substantially increase the concentration of proteins in the final preparation. Our method, which we call Enriched Platelet Factors (EnPLAF), is a basis for development of standardized method for delivery of GF to ovaries towards restoration of ovarian function, supporting recruitment and maturation of oocytes.

We call it Enoobio procedure.

The Enoo Protocol


Our primary technology, Enriched Platelet Factors (EnPLAF) is a medical breakthrough process that involves deriving beneficial biological factors naturally from the patient’s own blood. By using our proprietary EnPLAF technology, we have been able to improve healing, regeneration and provide pain relief without chemicals, drugs or genetic enhancements of any kind.

Our medical research and development team came together through their common study of Platelet Rich Plasma (PRP) which had been used as an agent of acceleration for healing and cell growth. In developing ways to provide pain relief, accelerated healing and regeneration benefits, but without all the drawbacks associated with PRP , our scientists developed a new technology to harness the active “Enriched Platelet Factors” contained in blood. Through EnPLAF, we are able to provide safe, convenient, highly efficacious, and cost-effective therapy options.

The Enoo Protocol

How it Works

Polycystic ovarian failure and premature ovarian failure are the leading causes of infertility in women. These conditions cause hormonal imbalance, irregular or impaired ovulation and the latter causes the loss of viable eggs in the ovaries.

The EnPLAF contains important growth factors such as TGFb, FGF ,IGF-1, IGFBP3, VEGF, PDGF-BB, HGF, EGF and cytokines.

Multiple tests by ELISA method, which had been conducted by independent sources, have demonstrated 5-10 times more efficient harvest of GF, comparing to the most known PRP preparation methods.

All these growth factors are derived from the patient’s own blood and are concentrated to maintain vascularisation and paracrine effects within the tissue.

The Enoo Protocol


Autologous PRP-based procedures, whereas EnPLAF is a version of PRP, are uniquely regarded as safe by the FDA and the EU’s Council of Competent Authorities. In the EU and US, autologous plasma transfusions are regarded as one of the safest possible procedures, and are used in the procedure of a variety of conditions as designated through the sole judgment of the clinician. Unlike procedures that use hormones or stem cell technology, blood transfusions require only limited oversight to ensure safety. In the case of our procedures, the subject’s own blood is used in combination with platelet activator of pharmaceutical grade, which are completely used up in the process and are not part of the final preparation. PRP activation by calcium gluconate or otherwise is known practice in other applications, which FDA has not attempted to regulate. EnPLAF protocol is a variation of autologous activated PRP.